Structure (A2c399e2 Baba 441a 8598 Bc8fa0e4dad9 01)
Teriflunomide Tablet, Film Coated
Product Images NDC 68254-5010
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Teriflunomide (NDC 68254-5010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Concord Biotech Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1: Kaplan-meier Plot Of Time To Disability Progression Sustained For 12 Weeks (study 1) (A2c399e2 Baba 441a 8598 Bc8fa0e4dad9 02)
This text appears to be a table showing the number at risk over different weeks for a placebo group, a group treated with 7mg Terflunomide, and a group treated with 14mg Teriflunomide. The data seems related to a clinical trial or study evaluating the effects of these treatments over time.*
Figure 2: Kaplan-meier Plot Of Time To Disability Progression Sustained For 12 Weeks (study 2) (A2c399e2 Baba 441a 8598 Bc8fa0e4dad9 03)
This text provides information on a clinical trial comparing the effectiveness of 7mg, 14mg, and placebo treatments of Teriflunomide in disability progression over a span of 12 weeks. The data includes the percentage data for Disability Progression Sustained for 12 weeks for each treatment group. The results indicate numerical values for each week compared between the placebo, 7mg, and 14mg Teriflunomide groups. The statistical significance is noted as well with the comparison "14mg vs. Placebo, p<0.05". The information can be used for evaluating the efficacy of Teriflunomide in managing disability progression.*
Image (A2c399e2 Baba 441a 8598 Bc8fa0e4dad9 04)
This tablet contains 7 mg of teriflunomide and is intended for oral intake once a day. It is important to keep it away from children and store it at a temperature range of 20°C to 25°C (68°F to 77°F), with some flexibility for excursions between 15°C and 30°C (59°F to 86°F). The medication guide should be dispensed along with each tablet. The tablets are manufactured by Concord Biotech Limited in Ahmedabad, Gujarat, India.*
Image (A2c399e2 Baba 441a 8598 Bc8fa0e4dad9 05)
Each tablet of this medication contains 14 mg of teriflunomide and is meant to be taken orally once daily. It is crucial to keep the tablets out of reach of children. The recommended storage temperature is between 20°C to 25°C, with excursions allowed to 15°C to 30°C. The accompanying Medication Guide should be dispensed to each patient along with the tablets. This product is manufactured by Concord Biotech Limited in India.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
